Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

NCT07573215 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Metastatic Pancreas Adenocarcinoma
Pancreatic Cancer
Pancreatic Cancer Metastatic
Pancreatic Adenocarcinoma Metastatic
Pancreatic Adenocarcinoma
Pancreatic Adenosquamous Carcinoma

Interventions

DRUG: daraxonrasib

Sponsor

Revolution Medicines, Inc.